Substituted alkylcarbonyl and arylcarbonyl compounds

Cpds. of formula (I) and their acid salts are new. X is O, S, HN or NR2. p is 1 or 2; Y is H, 1-6C alkyl, OH, Cl, F, Br, 1-6C alkoxy -CF3, NO2 or NH2 where p is 1. Y is lower alkoxy when P is 2 and X is O. R2 is lower, aryl or cycloalkyl, ariyl, alkanoyl or phenyl sulphonyl. Z is CH or N. n is 2,3,4 or 5. R is H, alkyl, 1-6C alkoxy, hydroxyl, carboxyl, Cl, F, Br, I, amino 1-6C mono-dialkyl amino, NO2, lower alkyl thio, OCF3, cyano, acylamino, CF3, trifluoroacetyl or amino carbonyl. A number of cpds. are specifically claimed. e.g. 1(4-(3(4-(1H-indazol-3-yl)-1- piperazinyl)propoxy)-3 methoxyphenyl)ethanone, or a pharmaceutically acceptable acid salt. The process for preparing (I) is claimed. Pref. parenteral dose contains 0.5-100 mg of active cpd. In the present invention there are disclosed substituted alkylcarbonyl and arylcarbonyl compounds of the general formula IA, in which J represents a phenyl group or a methyl group, G represents a methoxy group, a bromine atom, a methylmercapto group or a methyl group and m is 1 or 2. These compounds represent intermediates for preparing substituted N- (aryloxyalkyl)heteroarylpiperidines and -heteroarylpiperazines, which are efficient antipsychotic and analgesic agents.